Reinfection in patients with lyme disease

Clinical Infectious Diseases

Volumn 45, Issue 8, 2007, Pages 1032-1038

  Nadelman, Robert B ^a   Wormser, Gary P ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFALEXIN; IMMUNOLOGIC FACTOR; PENICILLIN G;

BORRELIA INFECTION; ERYTHEMA CHRONICUM MIGRANS; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; INFECTION RISK; LYME DISEASE; PRIORITY JOURNAL; REINFECTION; REVIEW; SEROCONVERSION; SERODIAGNOSIS; IMMUNOLOGY; INCIDENCE; PATHOLOGY; PATHOPHYSIOLOGY; RECURRENT DISEASE; UNITED STATES;

HUMANS; INCIDENCE; LYME DISEASE; RECURRENCE; UNITED STATES;

EID: 34848848694     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/521256     Document Type: Review

References (51)

1. Centers for Disease Control and Prevention; Jajosky RA, Hall PA, Adams DA, et al. Summary of notifiable diseases - United States, 2004. MMWR Morb Mortal Wkly Rep 2006; 53:1-79.
2. Stanek G, Strle F. Lyme borreliosis. Lancet 2003; 362:1639-47.
3. Hollström E. Penicillin treatment of erythema migrans Afzelius. Acta Derm Venereol 1958; 38:285-9.
4. Weber K, Schierz G, Wilske B, et al. Reinfection in erythema migrans disease. Infection 1986; 14:32-5.
5. Cartter ML, Hadler JL. Reinfection with Borrelia burgdorferi. Conn Med 1989; 53:376-7.
6. Gustafson R, Svenungsson B, Forsgren M, Gardulf A, Granstrom M. Two-year survey of the incidence of Lyme borreliosis and tick-borne encephalitis in a high-risk population in Sweden. Eur J Clin Microbiol Infect Dis 1992; 11:894-900.
7. Salazar JC, Gerber MA, Goff CW. Long-term outcome of Lyme disease in children given early treatment. J Pediatr 1993; 122:591-3.
8. Shadick NA, Phillips CB, Logigian EL, et al. The long-term clinical outcomes of Lyme disease: a population-based retrospective cohort study. Ann Intern Med 1994; 121:560-7.
9. Aberer E, Kehldorfer M, Binder B, Schauperi H. The outcome of Lyme borreliosis in children. Wien Klin Wochenschr 1999; 111:941-4.
10. Nowakowski J, Nadelman RB, Sell R, et al. Long-term follow-up of patients with culture-confirmed Lyme disease. Am J Med 2003; 115:91-6.
11. Bennet L, Berglund J. Reinfection with Lyme borreliosis: a retrospective follow-up study in southern Sweden. Scand J Infect Dis 2002; 34:183-6.
12. Gerber MA, Shapiro ED, Burke GS, Parcells VJ, Bell GL. Lyme disease in children in southeastern Connecticut. Pediatric Lyme Disease Study Group. N Engl J Med 1996; 335:1270-4.
13. Nowakowski J, Schwartz I, Nadelman RB, Liveris D, Aguero-Rosenfeld M, Wormser GP. Culture-confirmed infection and reinfection with Borrelia burgdorferi. Ann Intern Med 1997; 127:130-2.
14. Golde WT, Robinson-Dunn B, Stobierski MG, et al. Culture-confirmed reinfection of a person with different strains of Borrelia burgdorferi sensu stricto. J Clin Microbiol 1998; 36:1015-9.
15. Smith RP, Schoen RT, Rahn DW, et al. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann Intern Med 2002; 136:421-8.
16. Luger SW, Paparone P, Wormser GP, et al. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother 1995; 39:661-7.
17. Wormser GP, Ramanathan R, Nowakowski J, et al. Duration of antibiotic therapy for early Lyme disease: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003; 138:697-704.
18. Krause PJ, Foley DT, Burke GS, et al. Reinfection and relapse in early Lyme disease. Am J Trop Med Hyg 2006; 75:1090-4.
19. Nowakowski J, McKenna D, Nadelman RB, et al. Failure of treatment with cephalexin for Lyme disease. Arch Fam Med 2000; 9:563-7.
20. New York State Department of Health. Communicable disease annual reports and related information. Available at: http://www.health.state.ny.us/statistics/ diseases/communicable/index.htm. Accessed 6 September 2007.
21. Nadelman RB, Nowakowski J, Fish D, et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med 2001; 345:79-84.
22. Phillips CB, Liang MH, Sangha O, et al. Lyme disease and preventive behaviors in residents of Nantucket Island, Massachusetts. Am J Prev Med 2001; 20:219-24.
23. Wikel SK, Ramachandra RN, Bergman DK, Burkot TR, Piesman J. Infestation with pathogen-free nymphs of the tick Ixodes scapularis induces host resistance to transmission of Borrelia burgdorferi by ticks. Infect Immun 1997; 65:335-8.
24. Richter D, Spielman A, Matuschka FR. Effect of prior exposure to noninfected ticks on susceptibility of mice to Lyme disease spirochetes. Appl Environ Microbiol 1998; 64:4596-9.
25. Trager W. Acquired immunity to ticks. J Parasitol 1939; 25:57-81.
26. Burke G, Wikel SK, Spielman A, et al. Hypersensitivity to ticks and Lyme disease risk. Emerg Infect Dis 2005; 11:36-41.
27. Nuttall PA, Trimnell AR, Kazimirova M, Labuda M. Exposed and concealed antigens as vaccine targets for controlling ticks and tick-borne diseases. Parasite Immunol 2006; 28:155-63.
28. Magnuson HJ, Thomas EW, Olansky S, Kaplan BI, De Mello L, Cutler JC. Inoculation syphilis in human volunteers. Medicine 1956; 35:33-82.
29. Steere AJ, Coburn J, Glickstein L. Lyme borreliosis. In: Goodman JL, Dennis DT, Sonenshine DE, eds. Tick-borne diseases of humans. Washington, DC: ASM Press, 2005:176-206.
30. Heikkila T, Seppala I, Saxen H, Panelius J, Yrjanainen H, Lahdenne P. Species-specific serodiagnosis of Lyme arthritis and neuroborreliosis due to Borrelia burgdorferi sensu stricto, B. afzelii, and B. garinii by using decorin binding protein A. J Clin Microbiol 2002; 40:453-60.
31. Wormser GP. Vaccination as a modality to prevent Lyme disease: a status report. Infect Dis Clin North Am 1999; 13:135-48.
32. Rose CD, Fawcett PT, Klein JD, Eppes SC, Caputo GM, Doughty RA. Reinfection in paediatric Lyme borreliosis. Ann Rheum Dis 1993; 52:695-6.
33. Maraspin V, Lotric-Furlan S, Cimperman J, Ruzic-Sabljic E, Strle F. Erythema migrans in the immunocompromised host. Wien Klin Wochenschr 1999; 111:923-32.
34. Piesman J, Dolan MC, Happ CM, et al. Duration of immunity to reinfection with tick-transmitted Borrelia burgdorferi in naturally infected mice. Infect Immun 1997; 65:4043-7.
35. Probert WS, Crawford M, Cadiz RB, LeFebvre RB. Immunization with outer surface protein (Osp) A, but not OspC, provides cross-protection of mice challenged with North American isolates of Borrelia burgdorferi. J Infect Dis 1997; 175:400-5.
36. Steere AC, Bartenhagen NH, Craft JE, et al. The early clinical manifestations of Lyme disease. Ann Intern Med 1983; 99:76-82.
37. Luft BJ, Dattwyler RJ, Johnson RC, et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans: a double-blind, randomized, controlled trial. Ann Intern Med 1996; 124:785-91.
38. Nadelman RB, Nowakowski J, Forseter G, et al. Failure to isolate Borrelia burgdorferi after antimicrobial therapy in culture-documented Lyme borreliosis associated with erythema migrans: report of a prospective study. Am J Med 1993; 94:583-8.
39. Berger BW, Johnson RC, Kodner C, Coleman L. Failure of Borrelia burgdorferi to survive in the skin of patients with antibiotic-treated Lyme disease. J Am Acad Dermatol 1992; 27:34-7.
40. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089-134.
41. Falco RC, McKenna DF, Daniels TJ, et al. Temporal relation between Ixodes scapularis abundance and risk for Lyme disease associated with erythema migrans. Am J Epidemiol 1999; 149:771-6.
42. Clover JR, Lane RS. Evidence implicating nymphal Ixodes pacificus (Acari: ixodidae) in the epidemiology of Lyme disease in California. Am J Trop Med Hyg 1995; 53:237-40.
43. Jarefors S, Bennet L, You E, et al. Lyme borreliosis reinfection: might it be explained by a gender difference in immune response? Immunology 2006; 118:224-32.
44. Nadelman RB, Gaidici AT, McKenna D, et al. Comparison of clinical manifestations of 1st vs 2nd episodes of erythema migrans (EM) [abstract P-51]. In: Program and abstracts of the 9th International Conference on Lyme Borreliosis and Other Tick-borne Diseases (New York). 2002.
45. Eiffert H, Hanefeld F, Thomssen, Christen HJ. Reinfection in Lyme borreliosis. Infection 1996; 24:437-9.
46. Christen HJ, Hanefeld F, Eiffert H, Thomssen R. Epidemiology and clinical manifestations of Lyme borreliosis in childhood: a prospective multicentre study with special regard to neuroborreliosis. Acta Paediatr Suppl 1993; 386:1-75.
47. Wormser GP, McKenna D, Carlin J, et al. Hematogenous dissemination in early Lyme disease. Ann Intern Med 2005; 142:751-5.
48. Brown SL, Hansen SL, Langone JJ. Role of serology in the diagnosis of Lyme disease. JAMA 1999; 282:62-6.
49. Kalish RA, McHugh G, Granquist J, Shea B, Ruthazer R, Steere AC. Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10-20 years after active Lyme disease. Clin Infect Dis 2001; 33:780-5.
50. Wormser GP, Nadelman RB, Nowakowski J, et al. Serologic evaluation of adult patients with first vs second episodes of erythema migrans using a qualitative and quantitative C6 antibody test [poster 122]. In: Program and abstracts of the 10th International Conference on Lyme Borreliosis and Other Tick-borne Diseases (Vienna, Austria). 2005:78.
51. Bacon RM, Biggerstaff BJ, Schriefer ME, et al. Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. J Infect Dis 2003; 187:1187-99.